Edwards Lifesciences announced today that it received CE mark approval for its Sapien M3 mitral valve replacement system.

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s ...

Edwards Lifesciences Corp.’s Sapien M3 secured CE mark for its Sapien M3 mitral valve replacement system for transfemoral treatment of patients with mitral valve disease who are ineligible for surgery ...

Edwards Lifesciences has received CE marking for its transfemoral transcatheter mitral valve replacement system, setting up ...

Opens in a new tab or window Based on the finalized national coverage determination (NCD) for transcatheter tricuspid valve replacement, Medicare will cover the procedure when used for an FDA ...

Valve CMO threatened the company would walk away from games if it didn't own the rights to Half-Life—'It wasn't an idle threat—we weren't going to take on all of the risk to make other people ...

The US Centers for Medicare & Medicaid Services (CMS) has finalized its national coverage determination (NCD) for transcatheter tricuspid valve replacement (TTVR) when used to treat patients with ...

CMS has approved Medicare and Medicaid coverage for transcatheter tricuspid valve replacement procedures for the treatment of symptomatic tricuspid regurgitation. The procedures will be subject to ...

The company develops a prosthetic valve device designed to improve the quality of life for those with tricuspid regurgitation (TR). Delivered through a minimally invasive procedure, the valve ...

Laplace Interventional’s device aims to offer an improvement to the quality of life to patients worldwide diagnosed with Tricuspid Regurgitation (TR). Laplace Interventional is developing a prosthetic ...